The present paper reports the clinicopathologic features of six cases of non-Hodgkin’s lymphoma of the larynx observed during the last 14 years. After careful clinical staging only 3 patients had isolated laryngeal lymphoma (stage IE). Radiotherapy was administered as initial treatment in all cases. These patients are alive and well after 12,6 and 1 years, respectively. Histologically, all laryngeal lymphomas of this study showed a diffuse pattern of growth. All lymphomas were of follicular center cell origin according to Lukes and Collins (29). Four cases were of low grade malignancy according to Lennert and Mohri (25), or grade I, according to the British (18) classification. The remaining two were of high grade malignancy or grade II. A careful histopathological diagnosis, which may separate other pathological conditions, and an appropriate staging, which may exclude dissemination of disease, are stressed as representing the basis for effective treatment. The applicability of current functional nomenclature is possible also in these extranodal lymphomas.

Keywords:
Non-Hodgkin’s lymphoma, Malignant lymphoma, Extranodal lymphoma, Larynx, Head and neck lymphoma, Laryngeal lymphoma
This content is only available via PDF.
© 1981 S. Karger AG, Basel
1981
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.